Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.

Avichai Shimoni, MD, Avital Rand, RN, BSN, Noga Shem-Tov, Izhar Hardan, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler, M.D.

Blood (2010) 116 (21): 3473.

https://doi.org/10.1182/blood.V116.21.3473.3473

Published: 2010

Journal Articles

Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation

Avichai Shimoni, MD, Avital Rand, RN, BSN, Noga Shem-Tov, MD, Izhar Hardan, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler, M.D.

Blood (2010) 116 (21): 2314.

https://doi.org/10.1182/blood.V116.21.2314.2314

Published: 2010

Journal Articles

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Avichai Shimoni, MD, Avital Rand, RN, Noga Shem-Tov, MD, Izhar Hardan, Yulia Volchek, MD, Hannah Maayaan, MD, Ronit Yerushalmi, Arnon Nagler, MD

Blood (2009) 114 (22): 2255.

https://doi.org/10.1182/blood.V114.22.2255.2255

Published: 2009

Journal Articles

Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.

Avichai Shimoni, MD, Izhar Hardan, MD, Avital Rand, RN, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 2002.

https://doi.org/10.1182/blood.V110.11.2002.2002

Published: 2007

Journal Articles

Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).

Avichai Shimoni, MD, Izhar Hardan, MD, Noga Shem-Tov, MD, Avital Rand, RN, Elena Ribakovsky, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 1650.

https://doi.org/10.1182/blood.V110.11.1650.1650

Published: 2007

Journal Articles

Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.

Avichai Shimoni, MD, Izhar Hardan, MD, Noga Shem-Tov, MD, Avital Rand, RN, Elena Ribakovsky, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 1668.

https://doi.org/10.1182/blood.V110.11.1668.1668

Published: 2007

Journal Articles

Treatment of Donor Graft Failure with Autologous or Allogenenic Stem-Cell Boost or a Second Allogeneic Transplant Based on Chimerism Testing.

Avichai Shimoni, MD, Noga Shem-Tov, MD, Avital Rand, RN, Elena Ribakovsky, MD, Ronit Yerushalmi, MD, Izhar Hardan, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 2998.

https://doi.org/10.1182/blood.V110.11.2998.2998

Published: 2007

NARROW

Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.

Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.

Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).

Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.

Treatment of Donor Graft Failure with Autologous or Allogenenic Stem-Cell Boost or a Second Allogeneic Transplant Based on Chimerism Testing.

Email alerts

ASH Publications

American Society of Hematology

Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.

Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.

Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).

Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.

Treatment of Donor Graft Failure with Autologous or Allogenenic Stem-Cell Boost or a Second Allogeneic Transplant Based on Chimerism Testing.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only